Trial Profile
An investigator initiated Phase 2 clinical trial of AB569 in patients with chronic lung infection caused by P. aeruginosa and other bacterial pathogens in COPD and/or CF
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Nitrite (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2018 According to an Arch Biopartners media release, the clinical team at Cincinnati Veterans Affairs Medical Center (CVAMC), in association with the University of Cincinnati College of Medicine plans to initiate this trial.
- 14 Nov 2016 New trial record